B - 144 Base Rates of Performance Validity Test Failure among Patients with Persistent COVID-Related Cognitive Concerns

Abstract Objective Data on performance invalidity in neuropsychological evaluations among patients with SARS-CoV-2-related cognitive concerns is limited. This study investigated the base rates of performance validity test (PVT) failure among a sample of neuropsychological referrals with persistent c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of clinical neuropsychology 2024-10, Vol.39 (7), p.1251-1251
Hauptverfasser: Sedgwick, Thomas A, Basurto, Karen S, Finley, John-Christopher A, Boulais, Brooke M, Phillips, Matthew S, Jennette, Kyle J, Soble, Jason H, Ellison, Rachael L, Pliskin, Neil H, Ulrich, Devin M
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Objective Data on performance invalidity in neuropsychological evaluations among patients with SARS-CoV-2-related cognitive concerns is limited. This study investigated the base rates of performance validity test (PVT) failure among a sample of neuropsychological referrals with persistent cognitive concerns following SARS-CoV-2 infection. Method Data were collected from 62 patients (27% male, 73% female) with subjective cognitive concerns following SARS-Cov-2 infection. The sample included ethnoracially diverse adult patients (M = 44.1 years, SD = 12.53) with an average of 15 years of education (SD = 2.97) who underwent comprehensive neuropsychological evaluations including freestanding (Test of Memory Malingering, Trial 1 [TOMM T1]) and embedded (Wechsler Adult Intelligence Scale-4th Edition Digit Span Reliable Digit Span [WAIS-IV DS RDS]; California Verbal Learning Test-Brief Form Forced Choice [CVLT-BF FC]; Brief Visuospatial Memory Test Recognition-Discrimination [BVMT RD]; Stroop Word Reading T-Score [Stroop Word T]) PVTs. Results A majority of the sample (63%) passed all PVTs, 9.7% of the sample failed ≥2 PVTs suggesting invalidity, and 27.4% of the sample failed exactly one PVT. On embedded PVTs, failure rates were as follows: WAIS-IV DS RDS: 11.3%, CVLT-BF FC: 1.6%, BVMT Rec-Dis: 8.1%, and Stroop Word T: 8.1%. The failure rate on TOMM Trial 1 was 19.4%. Conclusions Patients presenting with persistent cognitive concerns following SARS-CoV-2 infection demonstrated relatively low overall invalidity rates using an empirically established cut-off (≥2). Further research is needed to confirm the generalizability of the present findings, as well as to explore the implications of failure on one PVT and the implications of failure on embedded versus freestanding PVTs in this population.
ISSN:1873-5843
1873-5843
DOI:10.1093/arclin/acae067.305